… Rituximab is safe and effective for treating relapsing–… activity after discontinuation and dose
reduction. The objective of … after discontinuation or dose reduction of rituximab in patients …

… that rituximab reduced the annualized relapse rate … relapse rates were 0.37 in the rituximab
group and 0.84 in the placebo group (p = 0.04) at week 24. Rituximab dramatically reduced …

… suggested low-dose RTX can significantly reduce relapse rate and steroid … dose RTX on
the relapse in adult MCD patients. In addition, we aimed to use low-dose RTX to prevent relapse …

… that rituximab is associated with reduced annualized relapse … also showed that rituximab was
associated with reduced ARRs, … reported the relapse likelihoods after the rituximab therapy, …

… of a standard dose of RTX in maintaining remission, reducing relapse frequency and
withdrawing immunosuppression, in a group of adult patients with frequently relapsing and steroid-…

… in reducing the number of relapses and sparing immunosuppression in frequently relapsing
… We then analyzed the association of RTX therapy with the reduction of the rate of relapses …

… a significant reduction of both annualized relapse rates and … with four weekly doses of rituximab,
two patients relapsed just … differences in our experience with rituximab and that in Cree’s …

… relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m 2
weekly for a total of 8 planned doses. … to reduce the currently observed relapse rates in HCL. …

… It has been confirmed that rituximab prophylaxis reduced relapse incidence from 0.57
episodes per year to 0 episodes per year when compared with historical controls. …

… mofetil or azathioprine) had been unchanged for at least 3 months prior to study entry and
was continued at the same dose until month 6, after which a dose reduction was allowed. …